1. Home
  2. DGICA vs VALN Comparison

DGICA vs VALN Comparison

Compare DGICA & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DGICA

Donegal Group Inc.

HOLD

Current Price

$16.21

Market Cap

607.2M

Sector

Finance

ML Signal

HOLD

Logo Valneva SE

VALN

Valneva SE

HOLD

Current Price

$5.36

Market Cap

536.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DGICA
VALN
Founded
1986
2012
Country
United States
France
Employees
851
N/A
Industry
Property-Casualty Insurers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
607.2M
536.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
DGICA
VALN
Price
$16.21
$5.36
Analyst Decision
Hold
Strong Buy
Analyst Count
1
2
Target Price
$19.00
$15.50
AVG Volume (30 Days)
80.9K
81.4K
Earning Date
04-30-2026
05-07-2026
Dividend Yield
4.14%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$2.26
N/A
Revenue Next Year
N/A
$93.87
P/E Ratio
$7.82
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.29
$5.15
52 Week High
$21.06
$12.25

Technical Indicators

Market Signals
Indicator
DGICA
VALN
Relative Strength Index (RSI) 36.01 26.83
Support Level N/A $5.15
Resistance Level $17.75 $6.42
Average True Range (ATR) 0.39 0.24
MACD -0.11 0.09
Stochastic Oscillator 20.47 10.31

Price Performance

Historical Comparison
DGICA
VALN

About DGICA Donegal Group Inc.

Donegal Group Inc is an insurance holding company whose insurance subsidiaries and affiliates offer property and casualty insurance in 21 Mid-Atlantic, Midwestern, Southern, and Southwestern states. It includes three segments: Investments Function, Commercial Lines of Insurance, and Personal Lines of Insurance. The majority of revenue is from the commercial Lines segment. The commercial Lines segment consists mainly of commercial automobile, commercial multi-peril, and workers' compensation policies.

About VALN Valneva SE

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.

Share on Social Networks: